# Phase 3 Alzheimer Disease trials recruiting: 37 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials in phase 3 for Alzheimer Disease that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Alzheimer Disease trials: 37 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/alzheimer-disease

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 37
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 7, 2026 | NCT07752784 | Evaluate the Concordance Between PET Imaging of \[18F\]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV... | JYAMS PET Research & Development Limited | Phase 3 | Recruiting | Alzheimer's Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752784) |
| July 21, 2026 | NCT07717411 | A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease | Hoffmann-La Roche | Phase 3 | Recruiting | Alzheimer's Disease | 1,600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717411) |
| May 22, 2026 | NCT07602582 | A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). | Eli Lilly and Company | Phase 3 | Recruiting | Alzheimer Disease, Dementia, Plaque, Amyloid | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602582) |
| May 6, 2026 | NCT07571161 | Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease | Eli Lilly and Company | Phase 3 | Recruiting | Alzheimer Disease | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571161) |
| February 20, 2026 | NCT07422857 | Evaluate the Use of \[18F\]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function | JYAMS PET Research & Development Limited | Phase 3 | Recruiting | Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia | 316 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07422857) |
| January 7, 2026 | NCT07323914 | Clinical Analgesic Management in Dementia | Xuanwu Hospital, Beijing | Phase 3 | Recruiting | Alzheimer Disease | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07323914) |
| November 26, 2025 | NCT07251023 | Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia | Bigespas LTD | Phase 3 | Recruiting | Alzheimer Type Dementia | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07251023) |
| November 18, 2025 | NCT07234695 | LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Phase 3 | Recruiting | Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Dementia, Alzheimer Dementia (AD), Alzheimer... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07234695) |
| September 24, 2025 | NCT07191028 | Alzheimer's Disease THErapy With NEuroaid II | Moleac Pte Ltd. | Phase 3 | Not yet recruiting | Alzheimer's Disease Dementia | 350 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07191028) |
| September 17, 2025 | NCT07177352 | Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Hoffmann-La Roche | Phase 3 | Recruiting | Alzheimers Disease | 80,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177352) |
| August 27, 2025 | NCT07142954 | Epidemiology and Biomarker Study in Alzheimer's Disease | Eli Lilly and Company | Phase 3 | Recruiting | Alzheimer Disease | 3,400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07142954) |
| August 11, 2025 | NCT07116473 | To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) | Eidos Therapeutics, a BridgeBio company | Phase 3 | Not yet recruiting | Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial, Amyloid Cardiomyopathy, Amyloid Cardiomyopathy... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07116473) |
| August 11, 2025 | NCT07115238 | Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD | Sinotau Pharmaceutical Group | Phase 3 | Recruiting | Alzheimer Disease, Neurofibrillary Tangle | 354 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115238) |
| July 14, 2025 | NCT07062198 | Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease | ScandiBio Therapeutics AB | Phase 3 | Recruiting | Alzheimer Disease | 845 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07062198) |
| July 11, 2025 | NCT07060391 | A Prospective Multicenter RCT Study of Deep Jugular Lymphovenous Anastomosis in the Treatment of Alzheimer's Disease | Shanghai Jiao Tong University School of Medicine | Phase 3 | Not yet recruiting | Alzheimer's Disease | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07060391) |
| June 10, 2025 | NCT07011745 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease | Bristol-Myers Squibb | Phase 3 | Recruiting | Alzheimer's Disease | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011745) |
| June 10, 2025 | NCT07011732 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease... | Bristol-Myers Squibb | Phase 3 | Recruiting | Alzheimer Disease | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011732) |
| May 16, 2025 | NCT06976216 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Bristol-Myers Squibb | Phase 3 | Recruiting | Alzheimer's Disease | 586 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976216) |
| May 16, 2025 | NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Bristol-Myers Squibb | Phase 3 | Recruiting | Alzheimer's Disease | 586 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06976203) |
| April 27, 2025 | NCT06947941 | A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5) | Bristol-Myers Squibb | Phase 3 | Recruiting | Alzheimer Disease, Psychosis | 325 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06947941) |
| April 22, 2025 | NCT06937229 | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Bristol-Myers Squibb | Phase 3 | Recruiting | Alzheimer Disease, Agitation | 650 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06937229) |
| January 28, 2025 | NCT06797817 | Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain | Universidad de Almeria | Phase 3 | Not yet recruiting | Alzheimer Disease (AD) | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06797817) |
| November 22, 2024 | NCT06702124 | A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease | I.R.C.C.S. Fondazione Santa Lucia | Phase 3 | Recruiting | Alzheimer Disease | 348 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06702124) |
| September 19, 2024 | NCT06585787 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | Alzheimer Disease | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06585787) |
| August 21, 2024 | NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Eidos Therapeutics, a BridgeBio company | Phase 3 | Recruiting | Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies | 587 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563895) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 6 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 3 |
| JYAMS PET Research & Development Limited | 2 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 2 |
| Eidos Therapeutics, a BridgeBio company | 2 |
| ScandiBio Therapeutics AB | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| University of California, Irvine | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Sinotau Pharmaceutical Group | 1 |
| Bigespas LTD | 1 |
| Universidad de Almeria | 1 |
| Sichuan Jishengtang Pharmaceutical Co., Ltd. | 1 |
| University of Pennsylvania | 1 |
| Moleac Pte Ltd. | 1 |
| CereMark Pharma, LLC | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Samsung Pharmaceutical Co., Ltd. | 1 |
| Lantheus Biosciences Ltd. | 1 |
| I.R.C.C.S. Fondazione Santa Lucia | 1 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 1 |
| Xuanwu Hospital, Beijing | 1 |
| Zhejiang Provincial People's Hospital | 1 |
| [AB Science](https://specstream.ai/data/clinical-trials/company/ab-science) | 1 |
| University Hospital, Lille | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 12 |
| Japan | 10 |
| Spain | 10 |
| Argentina | 9 |
| France | 9 |
| Brazil | 8 |
| Canada | 8 |
| Italy | 8 |
| Greece | 6 |
| Australia | 6 |
| Germany | 6 |
| Poland | 6 |
| Puerto Rico | 6 |
| United Kingdom | 6 |
| South Korea | 6 |
| Portugal | 5 |
| Romania | 5 |
| Taiwan | 5 |
| Chile | 5 |
| Croatia | 4 |
| India | 4 |
| Bulgaria | 3 |
| Mexico | 3 |
| Netherlands | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [T-shirt printers in the United States](https://specstream.ai/data/businesses/t-shirt-printers/united-states)
- [Restaurants in the United States](https://specstream.ai/data/businesses/restaurants/united-states)
- [Peruvian restaurants in the United States](https://specstream.ai/data/businesses/peruvian-restaurants/united-states)
- [Mills in the United States](https://specstream.ai/data/businesses/mills/united-states)
- [Jamaican restaurants in the United States](https://specstream.ai/data/businesses/jamaican-restaurants/united-states)
